ArticleThoracic cancer2021

Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.

Chen Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.